Sorry, you have Javascript Disabled! To see this page as it is meant to appear, please enable your Javascript!

RENOWNED EXPERTS IN MICROBIOME HEALTH AND WELLNESS

IFF Health is an industry authority and leading voice for microbiome health and wellness.

chevron-top-d3ebe9

Insights and Expertise

Let our intelligence and expertise power your brand

With HOWARU® support and elite resources, we have more than 100 years of strain fermentation and production expertise with extensive clinical support and scientific documentation. IFF Health and HOWARU® is always emerging – visit often for the latest webinars, publications, studies, events and more.

LEARN MORE ABOUT EACH STRAIN FROM THESE PRECLINICAL AND CLINICAL STUDY ARTICLES

HN001™

De Alberti D, Russo R, Terruzzi F, et al. Lactobacilli vaginal colonisation after oral consumption of Respecta® complex: a randomised controlled pilot study. Arch Gynecol Obstet. 2015;292(4):861–867.
Russo R, Edu A, De Seta F. Study on the effects of an oral lactobacilli and lactoferrin complex in women with intermediate vaginal microbiota. Arch Gynecol Obstet. 2018;298(1):139-145.
Russo R, Superti F, Karadja E, De Seta F. Evidence-based mixture containing Lactobacillus strains and lactoferrin to prevent recurrent bacterial vaginosis: a double blind, placebo controlled, randomised clinical trial. Benef Microbes. 2019;10(1):19-26.
Russo R, Superti F, Karadja E, De Seta F. Randomised clinical trial in women with recurrent vulvovaginal candidiasis: efficacy of probiotics and lactoferrin as maintenance treatment. Mycoses. 2018;62(4):328-335.
Slykerman RF, Hood F, Wickens K, et al. Effect of Lactobacillus rhamnosus HN001 in pregnancy on postpartum symptoms of depression and anxiety: A randomized double-blind placebo-controlled trial. EBioMedicine. 2017;24:159-165.
Wickens K, Barthow C, Mitchell EA, et al. Effects of Lactobacillus rhamnosus HN001 in early life on the cumulative prevalence of allergic disease to 11 years. Pediatr Allergy Immunol. 2018 Dec;29(8):808-814. doi: 10.1111/pai.12982.
Wickens K, Barthow C, Mitchell EA, et al. Maternal supplementation alone with Lactobacillus rhamnosus HN001 during pregnancy and breastfeeding does not reduce infant eczema. Pediatr Allergy Immunol. 2018;29(3);296-302. doi:10.1111/pai.12874.
Wickens K, Black P, Stanley TV, et al. A differential effect of 2 probiotics in the prevention of eczema and atopy: a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2008;122(4):788-794.
Wickens K, Black P, Stanley TV, et al. A protective effect of Lactobacillus rhamnosus HN001 against eczema in the first 2 years of life persists to age 4 years. Clin Exp Allergy. 2012;42(7):1071-1079.
Wickens K, Stanley TV, Mitchell EA, et al. Early supplementation with Lactobacillus rhamnosus HN001 reduces eczema prevalence to 6 years: does it also reduce atopic sensitization? Clin Exp Allergy. 2013;43(9):1048-57.
Wickens KL, Barthow CA, Murphy R, et al. Early pregnancy probiotic supplementation with Lactobacillus rhamnosus HN001 may reduce the prevalence of gestational diabetes mellitus: a randomised controlled trial. Br J Nutr. 2017;117:804-813
Prescott et al. Supplementation with Lactobacillus rhamnosus or Bifidobacterium lactis probiotics in pregnancy increases cord blood interferon-gamma and breast milk transforming growth factor-beta and immunoglobin A detection Clin Exp Allergy. 2008 Oct;38(10):1606-14.
Murphy et al. Eczema-protective probiotic alters infant gut microbiome functional capacity but not composition: sub-sample analysis from a RCT Benef Microbes. 2019 Feb 8;10(1):5-17.
Morgan et al. Differential modification of genetic susceptibility to childhood eczema by two probiotics Clin Exp Allergy. 2014 Oct;44(10):1255-65.
Marlow et al. Differential effects of two probiotics on the risks of eczema and atopy associated with single nucleotide polymorphisms to Toll-like receptors Pediatr Allergy Immunol. 2015 May;26(3):262-271.

Lpc-37®

Ding WK, Shah NP. Acid, bile and heat tolerance of free and microencapsulated probiotic bacteria. J Food Sci. 2007;72:M446-450.
Engelbrektson A, Korzenik JR, Pittler A, et al. Probiotics to minimize the disruption of faecal microbiotia in healthy subjects undergoing antibiotic therapy. J Medical Microbiology. 2009;58:663-670.
Ouwehand AC, DongLian C, Weijian X, et al. Probiotics reduce symptoms of antibiotic use in a hospital setting: a randomized dose response study. Vaccine. 2014;32(4):458-463.
West et al. Probiotic supplementation for respiratory and gastrointestinal illness symptoms in healthy physically active individuals Clin Nutr. 2014 Aug;33(4):581-7.
Barker et al. Probiotics for Clostridium difficile infection in adults (PICO): Study protocol for a double-blind, randomized controlled trial Contemp Clin Trials. 2015 Sep;44:26-32.
Morovic, Ouwehand, et al. Safety evaluation of HOWARU ® Restore (Lactobacillus acidophilus NCFM, Lactobacillus paracasei Lpc-37, Bifidobacterium animalis subsp. lactis Bl-04 and B. lactis Bi-07) for antibiotic resistance, genomic risk factors, and acute toxicity Food Chem Toxicol. 2017 Dec;110:316-324.
Forssten, Ouwehand. Simulating colonic survival of probiotics in single-strain products compared to multi-strain products Microb Ecol Health Dis. 2017 Oct 17;28(1):1378061.
Barker, Duster, et al. A randomized controlled trial of probiotics for Clostridium difficile infection in adults (PICO) J Antimicrob Chemother. 2017 Nov 1;72(11):3177-3180.
De Wolfe et al. Oral probiotic combination of Lactobacillus and Bifidobacterium alters the gastrointestinal microbiota during antibiotic treatment for Clostridium difficile infection PLoS One. 2018 Sep 28;13(9):e0204253.

HOWARU® CALM

Patterson E, Griffin SM, Ibarra A, Ellsiepen E, Hellhammer J. Lacticaseibacillus paracasei Lpc-37® improves psychological and physiological markers of stress and anxiety in healthy adults: a randomized, double-blind, placebo-controlled and parallel clinical trial (the Sisu study). Neurobiol Stress. 2020;13:100277.
Patterson E, Stenman L, et al. Strain specific stress-modulating effects of candidate probiotics: A systematic screening in a mouse model of chronic restraint stress Behav Brain Res. 2020 Feb 3;379:112376.

HOWARU® Restore

Ouwehand AC, DongLian C, Weijian X, et al. Probiotics reduce symptoms of antibiotic use in a hospital setting: a randomized dose response study. Vaccine. 2014;32(4):458-463.
Engelbrektson A, Korzenik JR, Pittler A, et al. Probiotics to minimize the disruption of faecal microbiotia in healthy subjects undergoing antibiotic therapy. J Medical Microbiology. 2009;58:663-670.
Barker et al. Probiotics for Clostridium difficile infection in adults (PICO): Study protocol for a double-blind, randomized controlled trial Contemp Clin Trials. 2015 Sep;44:26-32.
Morovic, Ouwehand, et al. Safety evaluation of HOWARU ® Restore (Lactobacillus acidophilus NCFM, Lactobacillus paracasei Lpc-37, Bifidobacterium animalis subsp. lactis Bl-04 and B. lactis Bi-07) for antibiotic resistance, genomic risk factors, and acute toxicity Food Chem Toxicol. 2017 Dec;110:316-324.
Forssten, Ouwehand. Simulating colonic survival of probiotics in single-strain products compared to multi-strain products Microb Ecol Health Dis. 2017 Oct 17;28(1):1378061.
Barker, Duster, et al. A randomized controlled trial of probiotics for Clostridium difficile infection in adults (PICO) J Antimicrob Chemother. 2017 Nov 1;72(11):3177-3180.
De Wolfe et al. Oral probiotic combination of Lactobacillus and Bifidobacterium alters the gastrointestinal microbiota during antibiotic treatment for Clostridium difficile infection PLoS One. 2018 Sep 28;13(9):e0204253.

HN019™

Dalziel JE, Anderson RC, Peters JS, et al. Promotility action of the probiotic Bifidobacterium lactis HN019 extract compared with prucalopride in isolated rat large intestine. Frontiers in Neuroscience. 2017;11.
Gopal PK, Prasad J, Gill HS. Effects of the consumption of Bifidobacterium lactis HN019 (DR10 TM) and galacto-oligosaccharides on the microflora of the gastrointestinal tract in human subjects. Nutrition Research. 2003;23:1313-1328.
Ibarra A, Latreille-Barbier M, Donazzolo Y, Pelletier X, Ouwehand AC. Effects of 28-day Bifidobacterium animalis subsp.lactis HN019 supplementation on colonic transit time and gastrointestinal symptoms in adults with functional constipation: A double-blind, randomized, placebo-controlled and dose-ranging trial. Gut Microbes. 2017; Dec 11:0.
Miller LE, Lehtoranta L, Lehtinen MJ. The Effect of Bifidobacterium animalis ssp. lactis HN019 on cellular immune function in healthy elderly subjects: systematic review and meta-analysis. Nutrients. 2017;9:191.
Prasad J, Sazawal S, Dhingra U, Gopal PK. Detection of viable Bifidobacterium lactis HN019 (DR10TM) in stools of children during a synbiotic dietary intervention trial. Intl Dairy J. 2013;30:64-67.
Waller PA, Gopal PK, Leyer GJ, et al. Dose-response effect of Bifidobacterium lactis HN019^™ on whole gut transit time and functional gastrointestinal symptoms in adults. Scand J Gastroenterol. 2011;46(9):1057-1064.

Digestive health meta-analyses:

Miller et al. – meta-analysis, showing benefits for HN019 Probiotic supplementation decreases intestinal transit time: meta-analysis of randomized controlled trials World J Gastroenterol. 2013 Aug 7;19(29):4718-25. doi: 10.3748/wjg.v19.i29.4718.
Miller et al. – contemporary meta-analysis Contemporary meta-analysis of short-term probiotic consumption on gastrointestinal transit World J Gastroenterol. 2016 Jun 7;22(21):5122-31. doi: 10.3748/wjg.v22.i21.5122.

Article in relation to Protect 55+:

Ahmed et al. – Impact of consumption of different levels of Bifidobacterium lactis HN019 on the intestinal microflora of elderly human subjects J Nutr Health Aging. Jan-Feb 2007;11(1):26-31.

Bi-07®

Candela M, Turroni S, Centanni M, et al. Relevance of Bifidobacterium animalis subsp. lactis plasminogen binding activity in the human gastrointestinal microenvironment. Appl Environ Microbiol. 2011;77:7072-7076.
Engelbrektson A, Korzenik JR, Pittler A, et al. Probiotics to minimize the disruption of faecal microbiota in healthy subjects undergoing antibiotic therapy. J Medical Microbiology. 2009;58:663-670.
Leyer GJ, Li S, Mubasher ME, Reifer C, Ouwehand AC. Probiotic effects on cold and influenza-like symptom incidence and duration in children. Pediatrics. 2009;124(2):172-179.
Ouwehand AC, DongLian C, Weijian X, et al. Probiotics reduce symptoms of antibiotic use in a hospital setting: a randomized dose response study. Vaccine. 2014;32(4):458-463.
West et al. Probiotic supplementation for respiratory and gastrointestinal illness symptoms in healthy physically active individuals Clin Nutr. 2014 Aug;33(4):581-7.
Barker et al. Probiotics for Clostridium difficile infection in adults (PICO): Study protocol for a double-blind, randomized controlled trial Contemp Clin Trials. 2015 Sep;44:26-32.
Morovic, Ouwehand, et al. Safety evaluation of HOWARU ® Restore (Lactobacillus acidophilus NCFM, Lactobacillus paracasei Lpc-37, Bifidobacterium animalis subsp. lactis Bl-04 and B. lactis Bi-07) for antibiotic resistance, genomic risk factors, and acute toxicity Food Chem Toxicol. 2017 Dec;110:316-324.
Forssten, Ouwehand. Simulating colonic survival of probiotics in single-strain products compared to multi-strain products Microb Ecol Health Dis. 2017 Oct 17;28(1):1378061.
Barker, Duster, et al. A randomized controlled trial of probiotics for Clostridium difficile infection in adults (PICO) J Antimicrob Chemother. 2017 Nov 1;72(11):3177-3180.
De Wolfe et al. Oral probiotic combination of Lactobacillus and Bifidobacterium alters the gastrointestinal microbiota during antibiotic treatment for Clostridium difficile infection PLoS One. 2018 Sep 28;13(9):e0204253.

Bl-04®

Bartosch S, Woodmansey EJ, Paterson JC, McMurdo ME, Macfarlane GT. Microbiological effects of consuming a synbiotic containing Bifidobacterium bifidum, Bifidobacterium lactis and oligofructose in elderly persons, determined by real-time polymerase chain reaction and counting of viable bacteria. Clin Infect Dis. 2005;40:28-37.
Engelbrektson A, Korzenik JR, Pittler A, et al. Probiotics to minimize the disruption of faecal microbiotia in healthy subjects undergoing antibiotic therapy. J Medical Microbiology. 2009;58:663-670.
Ouwehand AC, DongLian C, Weijian X, et al. Probiotics reduce symptoms of antibiotic use in a hospital setting: a randomized dose response study. Vaccine. 2014;32(4):458-463.
Ouwehand AC, Nermes M, Collado MC, et al. Specific probiotics alleviate allergic rhinitis during the birch pollen season. World J Gastroenterology. 2009;15.
Turner RB, Woodfolk JA, Borish L, et al. Effect of probiotic on innate inflammatory response and viral shedding in experimental rhinovirus infection – a randomised controlled trial. Benef Microbes. 2017;8(2):207-215.
West NP, Horn PL, Pyne DB, et al. Probiotic supplementation for respiratory and gastrointestinal illness symptoms in healthy physically active individuals. Clin Nutr. 2014;33(4):581-587.
Lehtinen et al. Nasal microbiota clusters associate with inflammatory response, viral load, and symptom severity in experimental rhinovirus challenge Sci Rep. 2018 Jul 30;8(1):11411.

NCFM®

Andreasen AS, Larsen N, Pedersen-Skovsgaard T, et al. Effects of Lactobacillus acidophilus NCFM on insulin sensitivity and the systemic inflammatory response in human subjects. Br J Nutr. 2010;104:1831-1838.
Engelbrektson A, Korzenik JR, Pittler A, et al. Probiotics to minimize the disruption of faecal microbiotia in healthy subjects undergoing antibiotic therapy. J Medical Microbiology. 2009;58:663-670.
Kleeman EG, Klaenhammer TR. Adherence of Lactobacillus species to human fetal intestinal cells. J Dairy Sci. 1982;65:2063-2069.
Leyer GJ, Li S, Mubasher ME, Reifer C, Ouwehand AC. Probiotic effects on cold and influenza-like symptom incidence and duration in children. Pediatrics. 2009;124(2):172-179.
Ouwehand AC, DongLian C, Weijian X, et al. Probiotics reduce symptoms of antibiotic use in a hospital setting: a randomized dose response study. Vaccine. 2014;32(4):458-463.
Barker et al. Probiotics for Clostridium difficile infection in adults (PICO): Study protocol for a double-blind, randomized controlled trial Contemp Clin Trials. 2015 Sep;44:26-32.
Morovic et al. Safety evaluation of HOWARU ® Restore (Lactobacillus acidophilus NCFM, Lactobacillus paracasei Lpc-37, Bifidobacterium animalis subsp. lactis Bl-04 and B. lactis Bi-07) for antibiotic resistance, genomic risk factors, and acute toxicity Food Chem Toxicol. 2017 Dec;110:316-324.
Forssten et al. Simulating colonic survival of probiotics in single-strain products compared to multi-strain products Microb Ecol Health Dis. 2017 Oct 17;28(1):1378061.
Barker et al. A randomized controlled trial of probiotics for Clostridium difficile infection in adults (PICO) J Antimicrob Chemother. 2017 Nov 1;72(11):3177-3180.
De Wolfe et al. Oral probiotic combination of Lactobacillus and Bifidobacterium alters the gastrointestinal microbiota during antibiotic treatment for Clostridium difficile infection PLoS One. 2018 Sep 28;13(9):e0204253.
West et al. Probiotic supplementation for respiratory and gastrointestinal illness symptoms in healthy physically active individuals Clin Nutr. 2014 Aug;33(4):581-7.
Rousseaux et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors Nat Med. 2007 Jan;13(1):35-7.
Ringel-Kulka et al. Probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 versus placebo for the symptoms of bloating in patients with functional bowel disorders: a double-blind study J Clin Gastroenterol. 2011 Jul;45(6):518-25.
Ringel-Kulka et al. Lactobacillus acidophilus NCFM affects colonic mucosal opioid receptor expression in patients with functional abdominal pain – a randomised clinical study Aliment Pharmacol Ther. 2014 Jul;40(2):200-7.
Lyra et al. Irritable bowel syndrome symptom severity improves equally with probiotic and placebo World J Gastroenterol. 2016 Dec 28;22(48):10631-10642.

La-14®

Bertuccini L, Russo R, Iosi F, Superti F. Effects of Lactobacillus rhamnosus and Lactobacillus acidophilus on bacterial vaginal pathogens. Intl J Immunopathology Pharmacology. 2017;30(2):163-167.
De Alberti D, Russo R, Terruzzi F, et al. Lactobacilli vaginal colonisation after oral consumption of Respecta® complex: a randomised controlled pilot study. Arch Gynecol Obstet. 2015;292(4):861–867.
Elawadli I, Brisbin JT, Mallard BA, et al. Differential effects of lactobacilli on activation and maturation of mouse dendritic cells. Beneficial Microbes. 2014;5(3):323-334.
Jang SE, Jeong JJ, Choi SY, et al. Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus La-14 attenuate gardnerella vaginalis-infected bacterial vaginosis in mice. Nutrients. 2017;9:531; doi:10.3390/nu9060531.
Paineau D, Carcano D, Leyer G. Effects of seven potential probiotic strains on specific immune responses in healthy adults: a double-blind, randomized, controlled trial. FEMS Immunol Med Microbiol. 2008;53(1):107-113.
Russo R, Edu A, De Seta F. Study on the effects of an oral lactobacilli and lactoferrin complex in women with intermediate vaginal microbiota. Arch Gynecol Obstet. 2018;298(1):139-145.
Russo R, Superti F, Karadja E, De Seta F. Evidence-based mixture containing Lactobacillus strains and lactoferrin to prevent recurrent bacterial vaginosis: a double blind, placebo controlled, randomised clinical trial. Benef Microbes. 2019;10(1):19-26.
Russo R, Superti F, Karadja E, De Seta F. Randomised clinical trial in women with recurrent vulvovaginal candidiasis: efficacy of probiotics and lactoferrin as maintenance treatment. Mycoses. 2018;62(4):328-335.

B420™

Collado MC, Meriluoto J, Salminen S. Role of commercial probiotic strains against human pathogen adhesion to intestinal mucus. Lett Appl Microbiol. 2007;45: 454-460.
Hibberd AA, Yde CC, Ziegler ML, et al. Probiotic or synbiotic alters the gut microbiota and metabolism in a randomised controlled trial of weight management in overweight adults. Beneficial Microbes. 2019;10(2):121-135.
Klein A, Friedrich U, Vogelsang H, Jahreis G. Lactobacillus acidophilus 74-2 and Bifidobacterium animalis subsp lactis DGCC B-420 modulate unspecific cellular immune response in healthy adults. Eur J Clin Nutr. 2008;62:584-659.
Kok RG, de Waal A, Schut F, et al. Specific detection and analysis of a probiotic Bifidobacterium strain in infant feces. Appl Environ Microbiol. 1996;62:3668-3672.
Lindfors K, Blomqvist T, Juuti-Uusitalo K, et al. Live probiotic Bifidobacterium lactis bacteria inhibit the toxic effects induced by wheat gliadin in epithelial cell culture. Clin Exp Immunol. 2008;152:552-558.
Mokkala K, Laitinen K, Roytio H. Bifidobacterium lactis B-420 and fish oil enhance intestinal epithelial integrity in Caco-2 cells. Nutr Res. 2016;36:246-252.
Putaala H, Salusjarvi T, Nordstrom M, et al. Effect of four probiotic strains and Escherichia coli O157:H7 on tight junction integrity and cyclo-oxygenase expression. Res Microbiol. 2008;159;692-698.
Stenman LK, Lehtinen MJ, Meland N, et al. Probiotic with or without fiber controls body fat mass, associated with serum zonulin, in overweight and obese adults—Randomized controlled trial. EBioMedicine. 2016.Nov;13:190–200. http://dx.doi.org/10.1016/j.ebiom.2016.10.036.
Stenman LK, Waget A, Garret C, et al. Potential probiotic Bifidobacterium animalis ssp. lactis B-420 prevents weight gain and glucose intolerance in diet-induced obese mice. Beneficial Microbes. 2014;5:437-445.
Stenman LK, Waget A, Garret C, et al. Probiotic BB-420 and prebiotic polydextrose improve efficacy of antidiabetic drugs in mice. Diabetology & Metabolic Syndrome. 2015;7:75.
Amar et al. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment EMBO Mol Med. 2011 Sep;3(9):559-72.
Lehtinen et al. Nasal microbiota clusters associate with inflammatory response, viral load, and symptom severity in experimental rhinovirus challenge Sci Rep. 2018 Jul 30;8(1):11411.
Barker et al. Probiotics for Clostridium difficile infection in adults (PICO): Study protocol for a double-blind, randomized controlled trial Contemp Clin Trials. 2015 Sep;44:26-32.
Morovic et al. Safety evaluation of HOWARU ® Restore (Lactobacillus acidophilus NCFM, Lactobacillus paracasei Lpc-37, Bifidobacterium animalis subsp. lactis Bl-04 and B. lactis Bi-07) for antibiotic resistance, genomic risk factors, and acute toxicity Food Chem Toxicol. 2017 Dec;110:316-324.
Forssten et al. Simulating colonic survival of probiotics in single-strain products compared to multi-strain products Microb Ecol Health Dis. 2017 Oct 17;28(1):1378061.
Barker et al. A randomized controlled trial of probiotics for Clostridium difficile infection in adults (PICO) J Antimicrob Chemother. 2017 Nov 1;72(11):3177-3180.
De Wolfe et al. Oral probiotic combination of Lactobacillus and Bifidobacterium alters the gastrointestinal microbiota during antibiotic treatment for Clostridium difficile infection PLoS One. 2018 Sep 28;13(9):e0204253.

Videos

LEVERAGE YOUR MICROBIOME AND HEALTH AND WELLNESS INTELLIGENCE – WATCH OUR INFORMATIONAL VIDEOS

Q

Q

Q

Q

Q

Q

Q

Q

Q

Q

Q

Always_Evolving

我们不断发展，从不止步！欢迎关注和订阅“IFF Health动态” —— 随时了解

我们的创新进展，注册参与活动，收听播客，并获取更多资讯。

联系我们

快捷链接

关注我们

本网站涉及的有关益生菌对人体健康影响的公开科学数据、文章及任何内容，均为针对益生菌本身已经科学验证的数据，非我公司产品之宣传。我公司产品不用于诊断、治疗、或预防任何疾病。

版权所有©2023 IFF。 IFF、IFF标志以及所有标有™、℠或^®的商标和服务标记均由IFF或IFF的附属公司拥有，除非另有说明。HOWARU^®是IFF或其附属公司的注册商标，该网站上的所有信息均旨在为膳食补充剂生产商提供企业对企业的交流，而不是最终食品、饮料或补充剂产品的最终消费者。 FDA尚未对该声明进行评估。本产品无意于诊断、治疗、治愈或预防任何疾病。